{"id":478663,"date":"2020-04-09T11:38:01","date_gmt":"2020-04-09T11:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=478663"},"modified":"2020-04-09T11:38:01","modified_gmt":"2020-04-09T11:38:01","slug":"refractory-angina-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/refractory-angina-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_478663.html","title":{"rendered":"Refractory Angina Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Refractory<\/a><\/p>\n
\n
“Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030”<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

DelveInsight has launched a report on “Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030<\/a>”<\/p>\n

DelveInsight’s “ Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030″<\/strong> report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the Facts:<\/strong><\/p>\n

    \n
  1. The total prevalent cases of Refractory Angina in 7 major markets ranges from 29,17,196 in 2017.<\/li>\n
  2. The United States accounted for most prevalent cases of RA in 7MM with 19,05,602 cases in 2017.<\/li>\n
  3. Germany accounted for most number of prevalent cases of RA with 5,13,896 cases in 2017.<\/li>\n
  4. Japan accounted for 27,432 cases in 2017 which are expected to grow during the study period (2017–2030).<\/li>\n<\/ol>\n

     <\/p>\n

    Key facts of the report:<\/strong><\/p>\n

    1. Refractory Angina market report covers a descriptive overview and comprehensive insight of the Refractory Angina epidemiology and Refractory Angina market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Refractory Angina market report provides insights on the current and emerging therapies. <\/p>\n

    3. Refractory Angina market report offers a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. Refractory Angina market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Refractory Angina market.<\/p>\n

     <\/strong><\/p>\n

    Request for Sample Pages: <\/strong> https:\/\/www.delveinsight.com\/sample-request\/refractory-angina-market<\/a><\/p>\n

     <\/em><\/strong><\/p>\n

    “According the DelveInsight, higher Prevalence of Refractory Angina is observed among males as compared to females in 7MM.”<\/em><\/strong><\/p>\n

     <\/strong><\/p>\n

    Refractory Angina (RA)<\/strong> is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart. Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease (CAD). <\/p>\n

    Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms causes poor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization.<\/p>\n

    Patients with RA are a heterogeneous group that remain significantly limited by persistent debilitating chest discomfort despite optimal conventional therapy.<\/p>\n

     <\/p>\n

    “RA is classified on the basis of grading the pain. Among these sub-types, Class III contributes the major patient share of RA followed by Class IV angina.”<\/em><\/strong><\/p>\n

     <\/strong><\/p>\n

    Some of the key companies working on Refractory Angina are:<\/strong><\/p>\n